ACET Adicet Bio, Inc.

Nasdaq adicetbio.com


$ 0.69 $ 0.00 (-0.04 %)    

Wednesday, 05-Nov-2025 15:59:54 EST
QQQ $ 623.71 $ 4.94 (0.8 %)
DIA $ 473.39 $ 2.21 (0.47 %)
SPY $ 678.30 $ 2.47 (0.37 %)
TLT $ 88.96 $ -0.57 (-0.64 %)
GLD $ 365.25 $ 0.10 (0.03 %)
$ 0.69
$ 0.69
$ 0.68 x 100
$ 0.72 x 55
$ 0.66 - $ 0.71
$ 0.45 - $ 1.40
901,203
na
57.45M
$ 1.64
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-05-2025 09-30-2025 10-Q
2 08-07-2025 06-30-2025 10-Q
3 05-06-2025 03-31-2025 10-Q
4 03-06-2025 01-01-1970 10-K
5 11-06-2024 09-30-2024 10-Q
6 08-13-2024 06-30-2024 10-Q
7 05-14-2024 03-31-2024 10-Q
8 03-19-2024 12-31-2023 10-K
9 11-08-2023 09-30-2023 10-Q
10 08-09-2023 06-30-2023 10-Q
11 05-09-2023 03-31-2023 10-Q
12 03-15-2023 12-31-2022 10-K
13 11-08-2022 09-30-2022 10-Q
14 08-10-2022 06-30-2022 10-Q
15 05-12-2022 03-31-2022 10-Q
16 03-15-2022 12-31-2021 10-K
17 11-10-2021 09-30-2021 10-Q
18 08-12-2021 06-30-2021 10-Q
19 05-17-2021 03-31-2021 10-Q
20 03-12-2021 12-31-2020 10-K
21 11-05-2020 09-30-2020 10-Q
22 07-31-2020 06-30-2020 10-Q
23 05-07-2020 03-31-2020 10-Q
24 03-12-2020 12-31-2019 10-K
25 11-05-2019 09-30-2019 10-Q
26 08-14-2019 06-30-2019 10-Q
27 05-15-2019 03-31-2019 10-Q
28 03-18-2019 12-31-2018 10-K
29 11-13-2018 09-30-2018 10-Q
30 08-09-2018 06-30-2018 10-Q
31 05-10-2018 03-31-2018 10-Q
32 03-29-2018 12-31-2017 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 guggenheim-maintains-buy-on-adicet-bio-raises-price-target-to-8

Guggenheim analyst Yatin Suneja maintains Adicet Bio (NASDAQ:ACET) with a Buy and raises the price target from $7 to $8.

 adicet-bios-lupus-trial-delivers-100-response-setting-stage-for-phase-2

Adicet Bio reported strong Phase 1 lupus trial results with ADI-001, showing 100% response in nephritis patients and raising $8...

 adicet-bio-shares-initial-safety-and-efficacy-data-from-the-first-seven-patients-dosed-with-adi-001-in-the-ongoing-phase-1-study-in-patients-with-autoimmune-diseases

Clinical data to date supports a potentially transformational approach to treating autoimmune diseases with an off-the-shelf, o...

 guggenheim-reiterates-buy-on-adicet-bio-maintains-7-price-target

Guggenheim analyst Yatin Suneja reiterates Adicet Bio (NASDAQ:ACET) with a Buy and maintains $7 price target.

 adicet-bio-q2-eps-034-misses-030-estimate

Adicet Bio (NASDAQ:ACET) reported quarterly losses of $(0.34) per share which missed the analyst consensus estimate of $(0.30) ...

 hc-wainwright--co-assumes-adicet-bio-at-buy-announces-price-target-of-4

HC Wainwright & Co. analyst Robert Burns assumes Adicet Bio (NASDAQ:ACET) with a Buy rating and announces Price Target o...

 adicet-bio-q1-eps-031-beats-034-estimate

Adicet Bio (NASDAQ:ACET) reported quarterly losses of $(0.31) per share which beat the analyst consensus estimate of $(0.34) by...

 guggenheim-reiterates-buy-on-adicet-bio-maintains-7-price-target

Guggenheim analyst Yatin Suneja reiterates Adicet Bio (NASDAQ:ACET) with a Buy and maintains $7 price target.

 citizens-capital-markets-reiterates-market-perform-on-adicet-bioto-market-perform

Citizens Capital Markets analyst Reni Benjamin reiterates Adicet Bio (NASDAQ:ACET) from Market Perform to Market Perform.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION